on field durability tests of mechanical systems the use of the fatigue damage spectrum

Abstract: In the present paper the authors, starting from a previously proposed method for the combination and the synthesis of equivalent load conditions (by only managing PSD representations of the load conditions), developed a new approach based on the concept of Fatigue Damage Spectrum and on the system dynamics. The proposed approach was then validated by a durability test case, in which two different acceleration motion based load conditions, a norm load condition (by using laboratory test) and an operative one (by using acceleration measurements acquired during an experimental activity conducted on a transport vehicle) were compared

Photoproduction of electron-positron pairs in bent single crystals

The process of photoproduction of electron-positron pairs in bent single crystals is considered in this paper. In particular, it is shown that the probability of the process for gamma-quanta with energies from 100 GeV on is significantly higher than the one in an amorphous medium. A possible scenario for the experimental validation of the process is discussed and the positive features of the photoproduction in bent crystals compared to straight ones are underlined from the point of view of possible applications.Comment: 13 pages, 6 figure

Shock induction by arterial hypoperfusion of the gut involves synergistic interactions between the peripheral enkephalin and nitric oxide systems.

To determine whether critical splanchnic artery hypoperfusion can provoke systemic shock and to identify the roles of the peripheral opioid and nitric oxide (NO) systems in this process, various degrees of superior mesenteric artery hypoperfusion (SMA-H) were produced in anesthetized adult rabbits (n=40), and hemodynamic and metabolic indices were measured. Metabolic acidosis and irreversible hypodynamic shock occurred with SMA-H at levels representing 25–20% of mean baseline SMA blood flow. In 112 other rabbits subjected to SMA-H at 20% (SMA-H20%), we studied plasma NO and enkephalin (ENK) levels, cardiovascular reactivity to selected physiological agonists, effects of ENKs on plasma NO levels, and effects of peripheral opioid receptor blockade and inducible NO synthase (iNOS) inhibition. SMA-H20% progressively increased systemic blood levels of NO and ENKs. Exogenous ENK administration accentuated SMA-H20%-induced increases in plasma NO levels, and their cardiovascular depressing effects were significantly greater when they were administered during SMA-H20% (vs. administration under baseline conditions). Selective blockade of cardiovascular δ-opioid receptors improved hemodynamics, prevented shock irreversibility and reduced plasma NO levels; similar effects were obtained by selective iNOS inhibition. These findings demonstrate that critical arterial hypoperfusion of the gut can induce hypodynamic systemic shock through ENK-induced hyperactivation of cardiovascular δ-opioid receptors, which leads to increased plasma levels of NO related in part to increased iNOS activity. Since pronounced splanchnic artery hypoperfusion occurs in all advanced systemic shock states, selective δ-opioid receptor antagonists and/or iNOS inhibitors may prove to be useful in improving shock hemodynamics and metabolic derangements and/or preventing progression toward irreversibility

Multiplexing of encrypted data using fractal masks

This paper was published in OPTICS LETTERS and is made available as an electronic reprint with the permission of OSA. The paper can be found at the following URL on the OSA website: http://dx.doi.org/10.1364/OL.37.002895. Systematic or multiple reproduction or distribution to multiple locations via electronic or other means is prohibited and is subject to penalties under lawIn this Letter, we present to the best of our knowledge a new all-optical technique for multiple-image encryption and multiplexing, based on fractal encrypting masks. The optical architecture is a joint transform correlator. The multiplexed encrypted data are stored in a photorefractive crystal. The fractal parameters of the key can be easily tuned to lead to a multiplexing operation without cross talk effects. Experimental results that support the potential of the method are presented.This research was performed under grants TWAS-UNESCO Associateship Scheme at Centres of Excellence in the South, CONICET No. 0863 (Argentina), ANCYT PICT 1167 (Argentina), and Facultad de Ingenieria, Universidad Nacional de La Plata No. 11/I125 (Argentina), Sostenibilidad 2011-2012, and CODI (Universidad de Antioquia-Colombia). W. D. Furlan and J. A. Monsoriua acknowledge financial support from Ministerio de Economia y Competitividad (grant FIS2011-23175), Generalitat Valenciana (grant PROMETEO2009-077), and Universitat Politecnica de Valencia (grants PAID-05-11 and PAID-02-11), Spain.Barrera, J.; Tebaldi, M.; Amaya, D.; Furlan, W.; Monsoriu Serra, JA.; Bolognini, NA.; Torroba, RD.... (2012). Multiplexing of encrypted data using fractal masks. Optics Letters. 37(14):2895-2897. doi:10.1364/OL.37.002895S289528973714Refregier, P., & Javidi, B. (1995). Optical image encryption based on input plane and Fourier plane random encoding. Optics Letters, 20(7), 767. doi:10.1364/ol.20.000767Matoba, O., & Javidi, B. (1999). Encrypted optical memory system using three-dimensional keys in the Fresnel domain. Optics Letters, 24(11), 762. doi:10.1364/ol.24.000762Unnikrishnan, G., Joseph, J., & Singh, K. (2000). Optical encryption by double-random phase encoding in the fractional Fourier domain. Optics Letters, 25(12), 887. doi:10.1364/ol.25.000887Nomura, T. (2000). Polarization encoding for optical security systems. Optical Engineering, 39(9), 2439. doi:10.1117/1.1288369Tebaldi, M., Furlan, W. D., Torroba, R., & Bolognini, N. (2009). Optical-data storage-readout technique based on fractal encrypting masks. Optics Letters, 34(3), 316. doi:10.1364/ol.34.000316Situ, G., & Zhang, J. (2005). Multiple-image encryption by wavelength multiplexing. Optics Letters, 30(11), 1306. doi:10.1364/ol.30.001306Liu, Z., & Liu, S. (2007). Double image encryption based on iterative fractional Fourier transform. Optics Communications, 275(2), 324-329. doi:10.1016/j.optcom.2007.03.039Hwang, H.-E., Chang, H. T., & Lie, W.-N. (2009). Multiple-image encryption and multiplexing using a modified Gerchberg-Saxton algorithm and phase modulation in Fresnel-transform domain. Optics Letters, 34(24), 3917. doi:10.1364/ol.34.003917Matoba, O., & Javidi, B. (1999). Encrypted optical storage with angular multiplexing. Applied Optics, 38(35), 7288. doi:10.1364/ao.38.007288Fredy Barrera, J., Henao, R., Tebaldi, M., Torroba, R., & Bolognini, N. (2006). Multiplexing encryption–decryption via lateral shifting of a random phase mask. Optics Communications, 259(2), 532-536. doi:10.1016/j.optcom.2005.09.027Henao, R., Rueda, E., Barrera, J. F., & Torroba, R. (2010). Noise-free recovery of optodigital encrypted and multiplexed images. Optics Letters, 35(3), 333. doi:10.1364/ol.35.000333Barrera, J. F., Henao, R., Tebaldi, M., Torroba, R., & Bolognini, N. (2006). Multiple image encryption using an aperture-modulated optical system. Optics Communications, 261(1), 29-33. doi:10.1016/j.optcom.2005.11.055Mosso, F., Barrera, J. F., Tebaldi, M., Bolognini, N., & Torroba, R. (2011). All-optical encrypted movie. Optics Express, 19(6), 5706. doi:10.1364/oe.19.005706Monsoriu, J. A., Saavedra, G., & Furlan, W. D. (2004). Fractal zone plates with variable lacunarity. Optics Express, 12(18), 4227. doi:10.1364/opex.12.00422

Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study

AIM To report adalimumab (Ada) efficacy on articulargastrointestinal disease and health-related quality of life (HRQoL) in patients with enteropathic spondyloarthritis (ES). METHODS A cohort of 52 patients with ES was evaluated in the departments of gastroenterology and internal medicine. At baseline, all patients underwent assessment by an integrated gastro-rheumatologic evaluation of articular and gastrointestinal activity, as well patient reported outcomes (PROs) of the HRQoL questionnaires. After this integrated evaluation and following a specific working flowchart, the Ada anti-tumor necrosis factor (TNF)-inhibitor was assigned to a cohort of 30 patients and its clinical efficacy was evaluated at baseline and after 6-mo and 12-mo treatment by the following tests: (1) Ankylosing Spondylitis Disease Activity Score- C-Reactive Protein (ASDAS-CRP); Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Metrology Index (BASMI) for articular activity; (2) Inflammatory Bowel Disease Questionnaire (IBDQ), Crohn's Disease Activity Index (CDAI) and partial Mayo (pMayo) score for gastrointestinal symptoms and activity; and (3) Health Assessment Questionnaire (HAQ), Patient Global Assessment (PGA) and Short Form-36 health survey (SF-36) questionnaires for PROs of the HRQoL. RESULTS Integrated evaluation and management of the patients affected by ES, carried out simultaneously by a gastroenterologist and a rheumatologist, allowed clinicians to choose the optimal therapeutic strategy. In a cohort of 30 ES patients affected by active articular and gastrointestinal disease, or axial active articular inflammation, Ada led to fast and sustained improvement of both articular and gastrointestinal disease activities. In fact, all the clinimetric evaluation tests exploring articular or gastrointestinal activity, as well as all the HRQoL scores, showed a significant improvement having been achieved at the earliest (6-mo) assessment. This important clinical improvement was maintained at the 12-mo follow-up. Importantly, global and gastrointestinal quality of life significantly correlated with articular disease activity, providing evidence to support that the integrated evaluation is the best option to manage patients with ES. CONCLUSION Ada treatment, upon multidisciplinary (gastrorheumatologic) evaluation, significantly improves both articular and gastrointestinal inflammation, thereby improving the HRQoL in patients affected by ES

No efficacy of transcranial direct current stimulation on chronic migraine with medication overuse : a double blind, randomised clinical trial

Background: Transcranial direct current stimulation was suggested to provide beneficial effects in chronic migraine, a condition often associated with medication overuse for which no long-term therapy is available. Methods: We conducted a randomised controlled trial to assess long-term efficacy of transcranial direct current stimulation. Adults diagnosed with chronic migraine and medication overuse were assigned to receive in a 1:1:1 ratio anodal, cathodal, or sham transcranial direct current stimulation daily for five consecutive days, along with standardised drug withdrawal protocol. Primary outcome was 50% reduction of days of headache per month at 12 months. Co-secondary outcomes were 50% reduction of days of headache per month at 6 months, reduction of analgesic intake per month, and change in disability and quality of life, catastrophising, depression, state and trait anxiety, dependence attitude and allodynia intensity. Patients were not allowed to take any migraine prophylaxis drug for the entire study period. Results: We randomly allocated 135 patients to anodal (44), cathodal (45), and sham (46) transcranial direct current stimulation. At 6 and 12 months, the percentage of reduction of days of headache and number of analgesics per month ranged between 48.5% and 64.7%, without differences between transcranial direct current stimulation (cathodal, anodal, or the results obtained from the two arms of treatment, anodal plus cathodal) and sham. Catastrophising attitude significantly reduced at 12 months in all groups. There was no difference for the other secondary outcomes. Conclusions: Transcranial direct current stimulation did not influence the short and long-term course of chronic migraine with medication overuse after acute drug withdrawal. Behavioral and educational measures and support for patients' pain management could provide long-term improvement and low relapse rate. Trial registration number NCT04228809